Have a feature idea you'd love to see implemented?
Let us know!
KURA Kura Oncology Inc
Price (delayed)
$8.8
Market cap
$684.32M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.36
Enterprise value
$651.47M
Tipifarnib, is a potent, selective and orally bioavailable inhibitor of farnesyl transferase in-licensed from Janssen. Previously, tipifarnib was studied in more than 5,000 cancer patients and showed compelling and durable
Highlights
The debt has declined by 4.6% year-on-year
Kura Oncology's net income has decreased by 38% YoY and by 9% from the previous quarter
The quick ratio has contracted by 31% YoY and by 23% from the previous quarter
Key stats
What are the main financial stats of KURA
Market
Valuations
Earnings
Shares outstanding
77.76M
Market cap
$684.32M
Enterprise value
$651.47M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.59
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$197.55M
EBIT
-$195.94M
EBITDA
-$195.08M
Free cash flow
-$169.24M
Per share
Balance sheet
Liquidity
EPS
-$2.36
EPS diluted
-$2.36
Free cash flow per share
-$1.95
Book value per share
$5.53
Revenue per share
$0
TBVPS
$5.51
Total assets
$478.84M
Total liabilities
$55.07M
Debt
$16.63M
Equity
$423.77M
Working capital
$422.82M
Debt to equity
0.04
Current ratio
11.47
Quick ratio
11.28
Net debt/EBITDA
0.17
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-39.6%
Return on equity
-44.1%
Return on invested capital
-44.8%
Return on capital employed
-44.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KURA stock price
How has the Kura Oncology stock price performed over time
Intraday
-0.68%
1 week
-1.9%
1 month
-18.14%
1 year
-37.19%
YTD
-38.8%
QTD
-54.96%
Financial performance
How have Kura Oncology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$217.5M
Net income
-$197.55M
Gross margin
N/A
Net margin
N/A
The company's operating income fell by 41% YoY and by 9% QoQ
Kura Oncology's net income has decreased by 38% YoY and by 9% from the previous quarter
Growth
What is Kura Oncology's growth rate over time
Valuation
What is Kura Oncology stock price valuation
P/E
N/A
P/B
1.59
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 17% YoY and by 6% QoQ
The stock's P/B is 50% below its last 4 quarters average of 3.2 and 41% below its 5-year quarterly average of 2.7
The equity has contracted by 9% from the previous quarter
Efficiency
How efficient is Kura Oncology business performance
The return on equity has declined by 32% year-on-year and by 9% since the previous quarter
The return on invested capital has declined by 31% year-on-year and by 11% since the previous quarter
The ROA has contracted by 28% YoY and by 8% from the previous quarter
Dividends
What is KURA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KURA.
Financial health
How did Kura Oncology financials performed over time
The current ratio fell by 31% YoY and by 23% QoQ
The quick ratio has contracted by 31% YoY and by 23% from the previous quarter
The debt is 96% smaller than the equity
The equity has contracted by 9% from the previous quarter
The debt has declined by 4.6% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.